clinical trial · NCT01018511
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Astellas Pharma Europe B.V.·phase3·completed·n = 1,334
Benign Prostatic HyperplasiaLower Urinary Tract SymptomsPlacebo tamsulosin hydrochloride OCAS 0.4 mgPlacebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mgPlacebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mgtamsulosin hydrochloride OCAS 0.4 mgtamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
brief summary
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.
started
Jan 11, 2010
primary completion
Mar 1, 2011
completion
Mar 1, 2011
last updated
Dec 3, 2024
official title
A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol